EN | CN

Elpiscience Completes Series A Financing of 20 Million USD

August 30 , 2017 10:00

Shanghai, August 30, 2017. Elpiscience announces it has raised 20 million USD in series A financing, invested by Lilly Asia Ventures (LAV). Elpiscience intends to use the proceeds from the financing to initiate operation, expand IO pipeline and establish its own R&D platforms.

 

Elpiscience, established in June 2017 by Darren Ji, Hongtao Lu, and David Shen, is committed to leading the innovation and development of the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Leveraging the deep understanding of immunology and with its highly efficient execution capabilities, Elpiscience will focus on the most frontier targets in innate and adaptive immunities, and building a world-class pipelines in cancer treatment.

 

Dr. Darren Ji, co-founder and CEO of Elpiscience, said “We are delighted to be supported by one of the most leading biomedical venture capital firms at the beginning of our journey. I am on behalf of Elpiscience to express our deep attitude for LAV’s recognition and trust. We are thrilled to strive with like-minded partners to be the best possible immunotherapy biopharma company that could be.”

 

About Elpiscience

Elpiscience was established in June 2017 with the commitment to leading the innovation and development of the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpiscience was founded by a seasoned team that combined management talents and R&D abilities together, aiming to build a robust and sustainable IO pipeline to tackle the unmet clinical needs.

 

About Lilly Asia Venture (LAV)

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, we spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, we have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, we manage over $1.2 billion of committed capital. LAV has significant resources in China, with extensive local expertise in preclinical and clinical development, regulatory knowhow, and market insights.